GNLX - NASDAQ
Genelux Corporation
$3.00
+1.0%Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
At a Glance
Live Snapshotgnlx
Total Liabilities
Last Annual Value
7.48M
3-Year CAGR
-43%
5-Year CAGR
-27%
10-Year CAGR
-12%
Genelux Corporation Competitors Analysis of Total Liabilities
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Genelux Corporation NASDAQ:GNLX | 7.48M | -3.9% | -28.9% | N/A | |
 Aldeyra Therapeutics, Inc. NASDAQ:ALDX | 27.81M | -0.9% | 0.3% | 22.9% | |
 Codexis, Inc. NASDAQ:CDXS | 97.27M | 24.9% | 3.5% | 19.4% | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 20.69M | -16.2% | -11.7% | 8.7% | |
 Invivyd, Inc. NASDAQ:IVVD | 35.34M | -11.9% | -10.7% | N/A | |
 OmniAb, Inc. NASDAQ:OABI | 33.89M | -17.6% | -13.5% | N/A | |
 Pyxis Oncology, Inc. NASDAQ:PYXS | 38.11M | -7.4% | 15.3% | N/A | |
 SELLAS Life Sciences Group, Inc. NASDAQ:SLS | 7.47M | -19.3% | 4.2% | -14.8% | |
 Candel Therapeutics, Inc. NASDAQ:CADL | 73.27M | 37.1% | 23.9% | N/A | |
 Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO | 22.02M | -5.7% | -35.2% | N/A | |
15.65M | -57.1% | 11.9% | N/A |
Genelux Corporation Fair Value Envelope
Related Guides
Continue your GNLX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.